The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Estimates of benefits and harms of prophylactic use of aspirin in the general population
Open accessAbstract
BACKGROUND: Accumulating evidence supports an effect of aspirin in reducing overall cancer incidence and mortality in the general population. We reviewed current data and assessed the benefits and harms of prophylactic use of aspirin in the general population. METHODS: The effect of aspirin for site-specific cancer incidence and mortality, cardiovascular events was collated from the most recent systematic reviews. Studies identified through systematic Medline search provided data regarding harmful effects of aspirin and baseline rates of harms like gastrointestinal bleeding and peptic ulcer. RESULTS: The effects of aspirin on cancer are not apparent until at least 3 years after the start of use, and some benefits are sustained for several years after cessation in long-term users. No differences between low and standard doses of aspirin are observed, but there were no direct comparisons. Higher doses do not appear to confer additional benefit but increase toxicities. Excess bleeding is the most important harm associated with aspirin use, and its risk and fatality rate increases with age. For average-risk individuals aged 50-65 years taking aspirin for 10 years, there would be a relative reduction of between 7% (women) and 9% (men) in the number of cancer, myocardial infarction or stroke events over a 15-year period and an overall 4% relative reduction in all deaths over a 20-year period. CONCLUSIONS: Prophylactic aspirin use for a minimum of 5 years at doses between 75 and 325 mg/day appears to have favourable benefit-harm profile; longer use is likely to have greater benefits. Further research is needed to determine the optimum dose and duration of use, to identify individuals at increased risk of bleeding, and to test effectiveness of Helicobacter pylori screening-eradication before starting aspirin prophylaxis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Collaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Final Report on the Aspirin Component of the Ongoing Physicians' Health Study
Steering Committee of the Physicians' Health Study Research Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198907203210301 · Cited by 2,264
Population Trends in the Incidence and Outcomes of Acute Myocardial Infarction
Yeh, R. W., Sidney, S., Chandra, M., Sorel, M., Selby, J. V., & Go, A. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908610 · Cited by 1,735
Writing Group Members, Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., et al. (2012) · Circulation · doi:10.1161/cir.0b013e3182456d46 · Cited by 1,512 · cited 2×
“1Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK; 2Department of Epidemiology, IRCCS-Istituto di Ricerche Farmacologiche ‘Mario Negri’, Milan, Italy; 3Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston…”
BackgroundRothwell, P. M., Fowkes, F. G. R., Belch, J. F., Ogawa, H., Warlow, C. P., & Meade, T. W. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62110-1 · Cited by 1,497 · cited 6×
“Evidence for mortality reduction is based on a greater number of studies [2] and the effect size appears to be larger than for incidence—a 40% overall reduction or 52% reduction with at least 5 years of scheduled treatment [2, 4].”
BackgroundInfluentialSelf-citationA Randomized Trial of Aspirin to Prevent Colorectal Adenomas
Baron, J. A., Cole, B. F., Sandler, R. S., Haile, R. W., Ahnen, D., Bresalier, R., McKeown-Eyssen, G., Summers, R. W., Rothstein, R., Burke, C. A., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021735 · Cited by 1,416
Rothwell, P. M., Wilson, M., Elwin, C.-E., Norrving, B., Algra, A., Warlow, C. P., & Meade, T. W. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61543-7 · Cited by 1,351 · cited 4×
“Subsequent longterm follow-up of three trials of low-dose aspirin (75–300 mg/ day) use found a smaller (25%) but significant reduction in CRC incidence [4].”
BackgroundInfluentialSelf-citationLow-Dose Aspirin for the Prevention of Atherothrombosis
Patrono, C., García Rodríguez, L. A., Landolfi, R., & Baigent, C. (2005) · New England Journal of Medicine · doi:10.1056/nejmra052717 · Cited by 1,218
Rothwell, P. M., Wilson, M., Price, J. F., Belch, J. F., Meade, T. W., & Mehta, Z. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60209-8 · Cited by 984
Self-citationBurn, J., Gerdes, A.-M., Macrae, F., Mecklin, J.-P., Moeslein, G., Olschwang, S., Eccles, D., Evans, D. G., Maher, E. R., Bertario, L., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61049-0 · Cited by 952
Self-citationHuang, J.-Q., Sridhar, S., & Hunt, R. H. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07273-2 · Cited by 901
Aspirin use and risk of fatal cancer.
Thun, M. J., Namboodiri, M. M., Calle, E. E., Flanders, W. D., & Heath, C. W. (1993) · PubMed · Cited by 870
Rothwell, P. M., Price, J. F., Fowkes, F. G. R., Zanchetti, A., Roncaglioni, M. C., Tognoni, G., Lee, R., Belch, J. F., Wilson, M., Mehta, Z., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61720-0 · Cited by 839 · cited 7×
“However, recent evidence suggests that aspirin’s effect on overall mortality is mainly through a reduction in cancer deaths [2, 3, 41].”
BackgroundResultInfluentialSelf-citationAlgra, A. M., & Rothwell, P. M. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70112-2 · Cited by 831
Self-citationFlossmann, E., & Rothwell, P. M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60747-8 · Cited by 820
Self-citationCook, N. R., Lee, I.-M., Gaziano, J. M., Gordon, D., Ridker, P. M., Manson, J. E., Hennekens, C. H., & Buring, J. E. (2005) · JAMA · doi:10.1001/jama.294.1.47 · Cited by 796
Self-citationCuzick, J., Otto, F., Baron, J. A., Brown, P. H., Burn, J., Greenwald, P., Jankowski, J., La Vecchia, C., Meyskens, F., Senn, H. J., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70035-x · Cited by 714
Self-citationAspirin Use and Survival After Diagnosis of Colorectal Cancer
Chan, A. T. (2009) · JAMA · doi:10.1001/jama.2009.1112 · Cited by 557
U.S. Preventive Services Task Force* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-6-200903170-00008 · Cited by 533
Aspirin for the Chemoprevention of Colorectal Adenomas: Meta-analysis of the Randomized Trials
Cole, B. F., Logan, R. F., Halabi, S., Benamouzig, R., Sandler, R. S., Grainge, M. J., Chaussade, S., & Baron, J. A. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn485 · Cited by 476
Low-Dose Aspirin and Incidence of Colorectal Tumors in a Randomized Trial
Gann, P. H., Manson, J. E., Glynn, R. J., Buring, J. E., & Hennekens, C. H. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.15.1220 · Cited by 422
Aspirin Intake and Survival After Breast Cancer
Holmes, M. D., Chen, W. Y., Li, L., Hertzmark, E., Spiegelman, D., & Hankinson, S. E. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.7918 · Cited by 365
Parsonnet, J., Harris, R. A., Hack, H. M., & Owens, D. K. (1996) · The Lancet · doi:10.1016/s0140-6736(96)01501-2 · Cited by 333
Chan, F. K., To, K., Wu, J. C., Yung, M., Leung, W., Kwok, T., Hui, Y., Chan, H. L., Chan, C. S., Hui, E., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07272-0 · Cited by 329
Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy
Law, M., Wald, N., & Morris, J. (2003) · Health Technology Assessment · doi:10.3310/hta7310 · Cited by 327
Self-citationCook, N. R., Lee, I.-M., Zhang, S. M., Moorthy, M. V., & Buring, J. E. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-2-201307160-00002 · Cited by 315
Self-citationEffect of Aspirin or Resistant Starch on Colorectal Neoplasia in the Lynch Syndrome
Burn, J., Bishop, D. T., Mecklin, J.-P., Macrae, F., Möslein, G., Olschwang, S., Bisgaard, M.-L., Ramesar, R., Eccles, D., Maher, E. R., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801297 · Cited by 300
Self-citationAspirin and cancer risk: a quantitative review to 2011
Bosetti, C., Rosato, V., Gallus, S., Cuzick, J., & La Vecchia, C. (2012) · Annals of Oncology · doi:10.1093/annonc/mds113 · Cited by 297
Self-citationHippisley-Cox, J., Coupland, C., & Logan, R. (2005) · BMJ · doi:10.1136/bmj.331.7528.1310 · Cited by 243
Aspirin Dose and Duration of Use and Risk of Colorectal Cancer in Men
Chan, A. T., Giovannucci, E. L., Meyerhardt, J. A., Schernhammer, E. S., Wu, K., & Fuchs, C. S. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.09.035 · Cited by 242
Pignone, M., Earnshaw, S., Tice, J. A., & Pletcher, M. J. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-5-200603070-00007 · Cited by 204 · cited 1×
“Thus, analyses based only on effects on CVD benefits have suggested that aspirin is cost-effective only in individuals at high risk of CVD [38–40].”
BackgroundLow Doses of Acetylsalicylic Acid Increase Risk of Gastrointestinal Bleeding in a Meta-Analysis
Lanas, Á., Wu, P., Medin, J., & Mills, E. J. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.05.020 · Cited by 168
Mathers, J. C., Movahedi, M., Macrae, F., Mecklin, J., Moeslein, G., Olschwang, S., Eccles, D., Evans, D. G., Maher, E. R., Bertario, L., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70475-8 · Cited by 156
Self-citationFriis, S., Sørensen, H. T., McLaughlin, J. K., Johnsen, S. P., Blot, W. J., & Olsen, J. H. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600760 · Cited by 151
Papatheodoridis, G., Sougioultzis, S., & Archimandritis, A. J. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2005.10.006 · Cited by 143
U.S. Preventive Services Task Force* (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-5-200703060-00008 · Cited by 140
Roderick, P. J., Davies, R. J., Raftery, J., Crabbe, D., Pearce, R., Bhandari, P., & Patel, P. (2003) · Health Technology Assessment · doi:10.3310/hta7060 · Cited by 124
Kaufman, D. W., Kelly, J. P., Wiholm, B., et al. (1999) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01517.x · Cited by 124
Aspirin use and mortality from cancer in a prospective cohort study.
Ratnasinghe, L. D., Graubard, B. I., Kahle, L., Tangrea, J. A., Taylor, P. R., & Hawk, E. (2004) · PubMed · Cited by 124
Long-term Aspirin Use and Mortality in Women
Chan, A. T., Manson, J. E., Feskanich, D., Stampfer, M. J., Colditz, G. A., & Fuchs, C. S. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.6.562 · Cited by 108
Greving, J. P., Buskens, E., Koffijberg, H., & Algra, A. (2008) · Circulation · doi:10.1161/circulationaha.107.735340 · Cited by 102
Aspirin Use and Pancreatic Cancer Mortality in a Large United States Cohort
Jacobs, E. J., Connell, C. J., Rodriguez, C. B., Patel, A. V., Calle, E. E., & Thun, M. J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh084 · Cited by 95
Self-citationDaily Aspirin Use and Cancer Mortality in a Large US Cohort
Jacobs, E. J., Newton, C. C., Gapstur, S. M., & Thun, M. J. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs318 · Cited by 94
Self-citationThorat, M. A., & Cuzick, J. M. (2014) · European Journal of Epidemiology · doi:10.1007/s10654-014-9971-7 · Cited by 88
Self-citationLow-dose Aspirin and Cancer Mortality: A Meta-analysis of Randomized Trials
Mills, E. J., Wu, P., Alberton, M., Kanters, S., Lanas, Á., & Lester, R. T. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.01.017 · Cited by 70
Cost-Utility of Aspirin and Proton Pump Inhibitors for Primary Prevention
Earnshaw, S., Scheiman, J. M., Fendrick, A. M., McDade, C. L., & Pignone, M. P. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.525 · Cited by 54
Dhillon, P. K., Kenfield, S. A., Stampfer, M. J., & Giovannucci, E. L. (2010) · International Journal of Cancer · doi:10.1002/ijc.25811 · Cited by 48
Pignone, M. P., Earnshaw, S., McDade, C. L., & Pletcher, M. J. (2013) · Journal of General Internal Medicine · doi:10.1007/s11606-013-2465-6 · Cited by 19
Cited by
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,792
Inflammation and cancer: advances and new agents
Crusz, S. M., & Balkwill, F. R. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.105 · Cited by 1,184
The lung microenvironment: an important regulator of tumour growth and metastasis
Altorki, N. K., Markowitz, G. J., Gao, D., Port, J. L., Saxena, A., Stiles, B., McGraw, T., & Mittal, V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-018-0081-9 · Cited by 1,150
Madeo, F., Carmona-Gutierrez, D., Hofer, S. J., & Kroemer, G. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.01.018 · Cited by 630
Metadata
- Authors
- Cuzick, J., Thorat, M. A., Bosetti, C., Brown, P. H., Burn, J., Cook, N. R., Ford, L. G., Jacobs, E. J., Jankowski, J. A., La Vecchia, C., Law, M., Meyskens, F., Rothwell, P. M., Senn, H. J., & Umar, A.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2015-01
- Volume
- 26
- Issue
- 1
- Pages
- 47-57
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2110501221
- Cited by
- 382
- References
- 50
- FWCI
- 33.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.